In conclusion, due to the increased prevalence of GITR+ NK cells, attempts to use a GITR agonist in combination with PD-1 and/or TIGIT blocking antibodies may be a good future therapeutic strategy in HNSCC patients [513]. This evidence concerns the gene TNFRSF18 and head and neck squamous cell carcinoma.